pancreaticoduodenectomy
Conditions
Interventions
Group S:PCIA: sufentanil 0.05 mg/kg/h and ondansetron 12 mg diluted with saline to 150 ml
Group SN:PCIA: fufentanil 0.025 mg/kg/h, nalbuphine 0.025mg/kg/h and ondansetron 12 mg diluted with saline to 150 ml
Group N:PCIA: nalbuphine 0.05mg/kg/h and ondansetron 12 mg diluted with saline to 150 ml
Sponsors
Lanzhou University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients with middle and lower common bile duct cancer, periampullary cancer, duodenal malignancy and early pancreatic head cancer were definitely diagnosed; 2. Aged >=18 years patients undergoing selective pancreaticoduodenectomy; 3. ASA I-III.
Exclusion criteria
Exclusion criteria: 1. BMI >18.5kg/m2; 2. Those with a history of serious heart, brain, lung, liver and kidney diseases; 3. Preoperative blood pressure is more than 180/110 mmHg in patients with hypertension; 4. Those with neuromuscular system diseases and psychiatric disorders; 5. Those are suspected of abusing of narcotic analgesics or sedatives; 6. Those have a history of allergy to emulsion and opioids; 7. Those who are unwilling to cooperate or unable to communicate.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| heart rate;Noninvasive blood pressure;Respiratory frequency;Pulse oxygen saturation;Rasmay sedation score;Postoperative analgesia-related adverse reactions;VAS; effective pressing times of PCIA;the ratio of effective pressing times of PCIA and total pressing times;Time of pulling out catheter;Time of leaving the bed activity;Exhaust time; | — |
Secondary
| Measure | Time frame |
|---|---|
| Changes of liver and kidney function before and after operation;the degree of comfort score;Satisfaction score;Postoperative hospital duration;Total cost after operation; | — |
Countries
China
Contacts
Public ContactXie Jianqin
Lanzhou University Second Hospital
Outcome results
None listed